Tamer I. Khayal Sells 63,260 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) insider Tamer I. Khayal sold 63,260 shares of the company’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $108.54, for a total transaction of $6,866,240.40. Following the completion of the transaction, the insider now owns 9,792 shares in the company, valued at $1,062,823.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

TransMedics Group Stock Performance

TMDX stock opened at $127.99 on Friday. The firm has a market cap of $4.19 billion, a price-to-earnings ratio of -376.44 and a beta of 1.87. The firm has a 50-day simple moving average of $85.54 and a two-hundred day simple moving average of $77.08. TransMedics Group, Inc. has a one year low of $36.42 and a one year high of $129.66. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 EPS for the quarter, beating the consensus estimate of ($0.05) by $0.40. The firm had revenue of $96.90 million during the quarter, compared to analyst estimates of $83.78 million. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 8.29%. TransMedics Group’s revenue was up 132.9% on a year-over-year basis. During the same period last year, the firm posted ($0.08) EPS. On average, equities analysts forecast that TransMedics Group, Inc. will post 0.54 EPS for the current fiscal year.

Hedge Funds Weigh In On TransMedics Group

Hedge funds and other institutional investors have recently modified their holdings of the stock. Venturi Wealth Management LLC purchased a new position in shares of TransMedics Group in the 1st quarter valued at approximately $30,000. Fidelis Capital Partners LLC purchased a new position in shares of TransMedics Group in the 1st quarter valued at approximately $35,000. Cutler Group LLC CA raised its position in shares of TransMedics Group by 600.0% in the 3rd quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock valued at $38,000 after purchasing an additional 600 shares during the last quarter. RiverPark Advisors LLC purchased a new position in shares of TransMedics Group in the 3rd quarter valued at approximately $60,000. Finally, First Horizon Advisors Inc. raised its position in shares of TransMedics Group by 26.8% in the 4th quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock valued at $83,000 after purchasing an additional 222 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on TMDX. TD Cowen increased their target price on shares of TransMedics Group from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday. Piper Sandler reiterated an “overweight” rating and set a $120.00 target price (up from $95.00) on shares of TransMedics Group in a report on Wednesday. Morgan Stanley increased their target price on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 28th. Canaccord Genuity Group increased their target price on shares of TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Oppenheimer increased their target price on shares of TransMedics Group from $105.00 to $125.00 and gave the stock an “outperform” rating in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $119.00.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.